Tourmaline Bio, Inc. (TRML)
(Delayed Data from NSDQ)
$47.98 USD
+0.02 (0.04%)
Updated Oct 24, 2025 04:00 PM ET
After-Market: $47.97 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Tourmaline Bio, Inc. has a market cap of $1.23B, which represents its share price of $47.96 multiplied by its outstanding shares number of 25.69M. As a small-cap company, TRML's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
TRML 47.98 +0.02(0.04%)
Will TRML be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TRML based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for TRML
NVS Reports Positive Late-Stage Data on Kidney Disease Drug
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
TRML: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know
Other News for TRML
TRML's price falls by 0.02% on October 23, though its technical setup remains stable.
Catalyst Watch: Trump-Xi, Fed meeting, Honeywell spinoff, and Amazon headlines busy earnings week
TRML rises 0.13% on October 22, leaving the technical picture intact
Technical picture remains unchanged for TRML after it falls 0.04% on October 21
Novartis announces expiration of HSR Act waiting period of Tourmaline Bio offer